Trial Results

Protocol
Available Languages: English
Statistical Analysis Plan
Available Languages: English

Study of ALXN1820 in Healthy Adult Participants

Study Identifier:
ALXN1820-HV-101
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: ALXN1820 SC
  • Drug: ALXN1820 IV
  • Drug: Placebo SC
  • Drug: Placebo IV
Date
Jan 2021 - Sep 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A
Requirements Information
Sex
Female & Male
Age
N/A - N/A

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: ALXN1820 SC
  • Drug: ALXN1820 IV
  • Drug: Placebo SC
  • Drug: Placebo IV
Date
Jan 2021 - Sep 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A years
Requirements Information

Protocol Summary

This is a Phase 1, randomized, double-blind, placebo-controlled single and multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of ALXN1820 administered subcutaneously (SC) (ALXN1820 SC) and intravenously (IV) (ALXN1820 IV).

Trial Locations

Location
Status
Location
Research Site
Herston, Australia, 4006
Status
N/A
Location
Research Site
London, United Kingdom, SE1 1YR
Status
N/A
Location
Research Site
London, United Kingdom, SE5 9RS
Status
N/A